🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Atrial Fibrillation Detection Using MEMO Patch in Patients With Stroke of Unknown Cause

RecruitingNAAges 19 Years - anyAllAsan Medical Center
NCT07295769 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The purpose of this study is to evaluate the efficacy and safety of a wearable device in detecting previously undiagnosed atrial fibrillation through non-invasive long-term monitoring using a wearable single-lead ECG patch (MEMO Patch M, MEMO Patch2) in 100 patients with Embolic Stroke of Undetermined Source (ESUS) who require atrial fibrillation screening. Participants who meet all inclusion and exclusion criteria and provide written informed consent will wear the MEMO Patch M and undergo in-hospital telemetry monitoring using MEMO Cue for a minimum of 12 hours and up to 8 days. During hospitalization, 24-hour Holter monitoring will also be conducted. Before discharge, the investigator will review these results to determine whether implantable loop recorder (ILR) implantation is necessary. At the time of discharge, participants will wear MEMO Patch2 for up to 14 days for the first ECG m

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: Participants may take part in this clinical study only if they meet all of the following criteria: 1. Adults aged 19 years or older who voluntarily provide written informed consent to participate in the study 2. Patients diagnosed with ESUS (Embolic Stroke of Undetermined Source) 3. Patients who require in-hospital or out-of-hospital electrocardiographic (ECG) monitoring Exclusion Criteria: Participants who meet any of the following criteria cannot be enrolled in this clinical study: 1. Individuals already diagnosed with atrial fibrillation or atrial flutter 2. Individuals with a clearly identified cause of stroke 3. Individuals known to have allergic reactions to adhesives or hydrogels 4. Individuals who, in the investigator's judgment, have cognitive vulnerability that makes it difficult to understand the study information and voluntarily decide on participation 5. Any other individuals whom the principal investigator considers to be at potential risk by participating in the study or otherwise unsuitable for participation
💊

What it tests

  • MEMO Patch M and MEMO Patch2
📍

Where

1 site
Asan Medical Center
Seoul, South Korea
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy